Skip to main content


Log in

Macular detachment after successful intravitreal bevacizumab for myopic choroidal neovascularization

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript



To determine the incidence and features of macular retinal detachment (RD) after successful intravitreal injection of bevacizumab (IVB) for the treatment of myopic choroidal neovascularizations (CNVs).


Seventy-four eyes of 74 patients who received IVB for myopic CNV were studied. Fluorescein angiography (FA) and optical coherence tomography (OCT) were performed at baseline, at 1 week after IVB, and every month thereafter. The shortest follow-up period was 6 months.


Four eyes (5.4%) either developed or had increased macular RD after successful IVB. In the three eyes, macular RD newly developed 1 month after IVB despite the absence of dye leakage. The remaining eye had a limited area of macular RD at baseline and increased despite the disappearance of dye leakage from the CNV after the IVB. The four eyes that developed a macular RD had retinoschisis around the CNV before IVB, whereas none of the 70 other patients had a retinoschisis throughout the follow-up period. In all four eyes that either developed or had increased macular RD, outer lamellar holes were detected at the upper edge of the RD by OCT examinations, whereas none of the patients who did not develop a macular RD after IVB showed outer lamellar holes.


These results suggest that there is a risk of developing macular RD after IVB in eyes with myopic CNV. Periodic OCT examinations are recommended for patients with myopic CNV to search for RDs after IVB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others


  1. Steidl SM, Pruett RC. Macular complications associated with posterior staphyloma. Am J Ophthalmol. 1997;123:181–7.

    Article  CAS  PubMed  Google Scholar 

  2. Curtin BJ. Ocular findings and complications. In: Curtin BJ, editor. The myopias. Philadelphia: Harper & Row; 1985. p. 277–347.

    Google Scholar 

  3. Panozzo G, Mercanti A. Optical coherence tomography findings in myopic traction maculopathy. Arch Ophthalmol. 2004;122:1455–60.

    Article  PubMed  Google Scholar 

  4. Curtin BJ, Karlin DB. Axial length measurements and fundus changes of the myopic eye. Am J Ophthalmol. 1971;1:42–53.

    Article  Google Scholar 

  5. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia. Br J Ophthalmol. 2007;91:157–60.

    Article  PubMed  Google Scholar 

  6. Sakaguchi H, Ikuno Y, Gomi F, Kamei M, Sawa M, Tsujikawa M, et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol. 2007;91:161–5.

    Article  CAS  PubMed  Google Scholar 

  7. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology. 2007;114:2190–6.

    Article  PubMed  Google Scholar 

  8. Chang LK, Spaide RF, Brue C, Freund KB, Klancnik JM Jr, Slakter JS. Bevacizumab treatment for subfoveal choroidal neovascularization from causes other than age-related macular degeneration. Arch Ophthalmol. 2008;126:941–5.

    Article  CAS  PubMed  Google Scholar 

  9. Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol. 2009;147:94–100.

    Article  CAS  PubMed  Google Scholar 

  10. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol. 2010;149:458–64.

    Article  CAS  PubMed  Google Scholar 

  11. Chan WM, Lai TYY, Liu DTL, Lam DSC. Intravitreal bevacizumab (avastin) for myopic choroidal neovascularization: 1-year results of a prospective study. Br J Ophthalmol. 2009;93:150–4.

    Article  PubMed  Google Scholar 

  12. Chung EJ, Koh HJ. Retinal detachment with macular hole following combined photodynamic therapy and intravitreal bevacizumab injection. Korean J Ophthalmol. 2007;21:185–7.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Bando H, Ikuno Y, Choi JS, Tano Y, Yamanaka I, Ishibashi T. Ultrastructure of internal limiting membrane in myopic foveoschisis. Am J Ophthalmol. 2005;139:197–9.

    Article  PubMed  Google Scholar 

  14. Shimada N, Ohno-Matsui K, Yoshida T, Sugamoto Y, Tokoro T, Mochizuki M. Progression from macular retinoschisis to retinal detachment in highly myopic eyes is associated with outer lamellar hole formation. Br J Ophthalmol. 2008;92:762–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references


The authors thank Prof. Duco Hamasaki for his critical discussion throughout this study and revision of the final manuscript. This work was supported in part by research grants 19390441 and 19659445 from the Japan Society for the Promotion of Science, Tokyo, Japan.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Kyoko Ohno-Matsui.

About this article

Cite this article

Shimada, N., Ohno-Matsui, K., Hayashi, K. et al. Macular detachment after successful intravitreal bevacizumab for myopic choroidal neovascularization. Jpn J Ophthalmol 55, 378–382 (2011).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: